Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.

MLA

Massin, Pascale, et al. “Real-World Outcomes with Ranibizumab 0.5 Mg in Patients with Visual Impairment Due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.” Ophthalmic Research, vol. 62, no. 2, Oct. 2019, pp. 101–10. EBSCOhost, https://doi.org/10.1159/000497406.

APA

Massin, P., Creuzot-Garcher, C., Kodjikian, L., Girmens, J.-F., Delcourt, C., Fajnkuchen, F., Glacet-Bernard, A., Guillausseau, P.-J., Ponthieux, A., Blin, P., & Grelaud, A. (2019). Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study. Ophthalmic Research, 62(2), 101–110. https://doi.org/10.1159/000497406

Chicago

Massin, Pascale, Catherine Creuzot-Garcher, Laurent Kodjikian, Jean-François Girmens, Cecile Delcourt, Frank Fajnkuchen, Agnès Glacet-Bernard, et al. 2019. “Real-World Outcomes with Ranibizumab 0.5 Mg in Patients with Visual Impairment Due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.” Ophthalmic Research 62 (2): 101–10. doi:10.1159/000497406.